Search
EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreEHA European Hematology Exam 2018 Report
1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.
Meet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreMeet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreEHA-PTHiT Hematology Tutorial on Novel Treatment Approaches in Hematologic Malignancies
EHA in collaboration with the Polish Society for Hematology and Transfusion (PTHiT) have decided to postpone this highly anticipated Hematology Tutorial to a future date, to be announced.
Read moreMeet Eva Hellström-Lindberg, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…
Meet Eva Hellström-Lindberg, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- »